Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair

Current therapies for treatment of proliferative retinopathy focus on retinal neovascularization (RNV) during advanced disease and can trigger adverse side-effects. Here, we have tested a new strategy for limiting neurovascular injury and promoting repair during early-stage disease. We have recently...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouda, Abdelrahman Y., Xu, Zhimin, Suwanpradid, Jutamas, Rojas, Modesto, Shosha, Esraa, Lemtalsi, Tahira, Patel, Chintan, Xing, Ji, Zaidi, Syed A., Zhi, Wenbo, Stansfield, Brain K., Cheng, Paul Ning-Man, Narayanan, S. Priya, Caldwell, R. William, Caldwell, Ruth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424300/
https://www.ncbi.nlm.nih.gov/pubmed/36038541
http://dx.doi.org/10.1038/s41419-022-05196-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424300/
https://www.ncbi.nlm.nih.gov/pubmed/36038541
http://dx.doi.org/10.1038/s41419-022-05196-8

Ejemplares similares